Andrejs ERGLIS

Andrejs ERGLIS

Assoc. Prof. Andrejs ERGLIS

Faculty of Medicine
University of Latvia
Sarlotes iela 1a
Riga, LV 1001

Director and Leading investigator,
Research Institute of Cardiology,
University of Latvia,
Pilsonu iela 13,
Riga, LV1002

Chief, Latvian Centre of Cardiology,
Pauls Stradins Clinical University Hospital
Pilsonu iela 13
Riga, LV 1002
Phone: + 371 67069541
Fax: + 371 67069548
E-mail: [email protected]

Born: December 25, 1964, Riga, Latvia

Languages: Latvian, English, Russian

Main fields of interest and research:

Interventional Cardiology
Percutaneous Coronary Interventions for Complex Lesions
Intravascular Diagnostics
Acute Coronary Syndromes
Prevention, Registries and Outcome Research

Education:

MD, Riga Medical Institute, 1983-1989
Internship, Internal Medicine, Riga Medical Institute, 1989-1990
Postgraduate studies:

Radiology, Riga Medical Institute, 1990
Interventional Cardiology, Tallin Emergency Hospital, Estonia, 1990
Interventional Cardiology, Stanford University Medical Center, USA,1993
Interventional Cardiology, Monash Med. Centre, Australia, 1994
Interventional Cardiology, Catharina Hospital, The Netherlands, 1998
Interventional Cardioloy, San-Donato University Hospital, Milan, Italy, 1999

PhD (Dr. med.), University of Latvia, 2006

Thesis: Percutaneous coronary interventions for complex coronary lesions. The challenge of restenosis.

Experience:

Faculty of Medicine, University of Latvia:

Associate Professor, 2007-present

Research Institute of Cardiology, University of Latvia:

Assistant, 1984-2006
Leading Investigator, 2006-present
Director, 2008-present

Pauls Stradins Clinical University Hospital

Chief, Department of Interventional and Emergency Cardiology, Latvian Centre of Cardiology, 1999-present
Chief, Latvian Centre of Cardiology, 2005-present
Chairman, Strategic Council, 2006-present

Honours and Awards:

The Three Stars Order (Republic of Latvia), 2003

Professional Activities and Memberships:

Member, Latvian Society of Cardiology, 1994-present
Secretary, Baltic Society of Interventional Cardiology, 1998-2003
President, Baltic Society of Interventional Cardiology, 2004-present
President, Latvian Society of Cardiology, 2005-present
Fellow of the European Society of Cardiology, 2005-present
Fellow of the American Collage of Cardiology, 2005-present
Memeber, European Association for Percutaneous Cardiovascular Interventions (EAPCI), 2007-present

Recent/Representative Publications:

U. Kalnins, A. Erglis, S. Borovski. Exercise and pacing tests for diagnosis of single coronary artery disease. - J. Electrocardiology 1993: 26(2): 171-172.
K. Heidemanis, U. Kalnins, I. Dabina, I. Dinne, A. Erglis. A new aspect of antiatherogenic action of plasma high-density lipoproteins: inhibition of cholesterol biogenesis. - The Baltic Atherosclerosis J 1999; 1: 53-55.
P. Tretjakovs, U. Kalnins, I. Dabina, I. Dinne, A. Erglis, A.Jurka. Interaction between arachidonic acid and platelet phospholipids, and HDL-cholesterol metobolism in patients with coronary heart disease. - Acta Medica Austriac, 1999; 26(S49): 6-7.
P. Tretjakovs, U. Kalnins, I. Dabina, I. Dinne, A. Erglis, A. Jurka. Plasma high-density-lipoprotein cholesterol (HDL-C) correlates with sterol biogenesis and nitric oxide production in the platelet membranes of coronary artery disease (CAD) patients. - Chemistry and Physics of Lipids 1999; 101(2): 169-170.
P. Tretjakovs, U. Kalnins, I. Dabina, I. Dinne, A. Erglis, I. Kumsars, A. Jurka. Plasma HDL-cholesterol has an effect on noitric oxide production and arachidonic acid metabolism in the platelet membranes of coronary heart disease patients without LDL-hypercholesterolemia. - Med Sci Monit 2000; 6(3): 507-511.
P. Tretjakovs, U. Kalnins, I. Dabina, I. Dinne, A. Erglis, A. Jurka. Nitric oxide and cutaneous vasomor response in coronary artery disease patients. - Atheroslerosis 2000; 15(1): 11-12.
P. Tretjakovs, U. Kalnins, I. Dabina, I. Dinne, A. Erglis, I. Kumsars, Jurka A. Relationship between nitric oxide production and arachidonic acid metabolism in the platelet membranes of coronary artery disease patients. - Acta Universitatis Latviensis, Medicine 2001; 631(4): 134-143.
P. Tretjakovs, U. Kalnins, I. Dabina, I. Dinne, A. Erglis, G. Latkovskis, A. Jurka. Effect of HDL-cholesterol on nitric oxide production and turnover of phospholipids in platelet membranes in CAD patients. - Baltic Atherosclerosis Journal 2001, 2: 21-24.
V. Rudzite, A. Silava, U. Kalnins, A. Erglis, K. Trusinskis, M. Jaeger, D. Fuchs. Homocysteine, pyridoxal-5-phosphate and neopterin in patients with coronary heart disease. - Pteridines 2001; 12: 120-29.
V. Rudzite, A. Silava, U. Kalnins, A. Erglis, K. Trusinskis, M. Jaeger, D. Fuchs. Significance of the determination of serum neopterin and homocysteine concentrations as well as pyridoxal-5-phosphate deficiency in patients with coronary heart disease. - Pteridines 2001; 12: 130-134.
U. Kalnins, A. Erglis, I. Dinne, I. Kumsars, S. Jegere. Clinical outcomes of silicon carbide coated stents in patients with coronary artery disease. - Med Sci Monit 2002; 8(2): 16-20.
P. Tretjakovs, U. Kalnins, I. Dabina, A. Erglis, I. Dinne, A. Jurka, G. Latkovskis, A. Zvaigzne, V. Pirags. Arachidonic acid methabolism and nitric oxide production in platelet membranes of coronary artery disease patients with and without diabetes. - Proceedings of the Latvian Academy of Sciences, Section B 2002; 56(3): 109-113.
V. Rudzite, A. Jurika, U. Kalnins, A. Erglis, K. Trusinskis, S. Jegere, B. Frick, D. Fuchs. Comparing the sensitivity pf pyridoxal-5-phospate, homocysteine and neoptrin in coronary heart disease. - Pteridines 2002; 13(3): 100-103.
V. Rudzite, E. Jurika, U. Kalnins, A. Erglis, K. Trusinskis, S. Jegere. Changes in lipid metabolism in patients with coronary heart disease. - Proceedings of the Latvian Academy of Sciences, Section B 2002; 56(3): 109-113.
P. Tretjakovs, U. Kalnins, I. Dabina, A. Erglis, I. Dinne, A. Jurka, G. Latkovskis, A. Zvaigzne, V. Pirags. Nitric oxide production and arachidonic acid metabolism in platelet membranes of coronary heart disease patients with and without diabetes. - Medical Principles and Practice 2003; 12: 10-16.
M. Haude, T.F.M. Konorza, U. Kalnins, A. Erglis, K. Saunamäki, H.D. Glogar, E. Grube, R. Gil, A. Serra, H.G. Richard, P. Sick, R. Erbel for the heparin - COAted STents in small coronary arteries (COAST) trial investigators. Heparin-coated stent placement for treatment of stenoses in small coronary arteries of symptomatic patients. - Circulation 2003; 107: 1265-1270.
V. Rudzite, D. Fuchs, U. Kalnins, E. Jurika, A. Silava, A. Erglis, K. Trusinskis, S. Jegere. Prognostic value of tryptophan load test followed by serum kynurenine determination. Its comparison with pyridoxal-5-phosphate, kynurenine, homocysteine and neopterin amounts. - Adv Exp Med Biol 2003, 527: 307-315.
B. Frick, V. Rudzite, K. Schröcksnadel, U. Kalnins, A. Erglis, K. Trusinskis, D. Fuchs. Homocysteine, B vitamins and immune activation in coronary heart disease. - Pteridines 2003; 14: 82–87.
V. Rudzite, E. Jurika, D. Fuchs, U. Kalnins, A. Erglis, K. Trusinskis. Secondary risk factors in the progression of coronary artery disease. In: Proceedings of the 5^th International Congress on Coronary Artery Disease (Frontiers in Coronary Artery Disease), B.S.Lewis, D.A.Halon, M.Y. Flugelman, G.F.Gensini eds., Bologna (Italy), Monduzzi editore, 2003; 175–178.
V. Rudzite, E. Jurika, D. Fuchs, B. Wirteiter, U. Kalnins, A. Erglis, K. Trusinskis. Serum concentration of C-reactive protein, neopterin and phospholipids in patients with coronary artery disease. - Pteridines 2003; 14: 56–57.
B. Wirleitner, V. Rudzite, G. Neurauter, C. Murr, U. Kalnins, A. Erglis, K. Trusinskis, D. Fuchs. Immune activation and degradation of tryptophan in coronary heart disease. - Eur J Clin Invest, 2003, 33(7): 550-554.

A. Erglis, U. Kalnins, A. Saltups, I. Kumsars, I. Dinne, D. Sondore, I. Narbute, S. Jegere, U. Jaspers. The influece of balloon material on stent geometry and acute gain during intravascular ultrasound guided stenting. - Seminars in Cardiology, 2003; 9(2): 38-45.
V.Rudzite, E.Jurika, D.Fuchs, U.Kalnins, A.Erglis, K.Trusinskis. Indices of inflammation and other secondary risk factors in the progression of coronary artery disease (CAD). - Atherosclerosis Supplements 2004; 5: 38-39.
U. Kalnins, A. Erglis, A. Rudzitis M. Schneider, F. Kohler F. [Interventional cardiology in Latvia 1993 - 2003] - Dtsch Med Wochenschr 2004;129(Suppl 1): S29-32.

A. Erglis, U. Kalnins, A. Saltups, I. Kumsars, I. Narbute, S. Jegere, I. Dinne, D. Sondore, U. Jaspers. Simple barotrauma reduction during coronary stenting: Effect on six-month neointimal proliferation. Riga non-compliant balloon study. Proceedings of the Latvian Academy of Sciences, Section B, 2004;58(3/4): 120-125.
V. Rudzite, E. Jurika, K. Schroecksnadel, U. Kalnins, A. Erglis, K. Trusinskis, D. Fuchs. Usefulness of neopterin, C-reactive protein, homocysteine, pyridoxal-5-phosphate, and phospholipid determination in coronary artery disease. - Pteridines 2005; 16(1): 15-21.
V. Rudzite, E. Jurika, D. Fuchs, U. Kalnins, A. Erglis, K. Trusinskis. Inflammation, homocysteine, pyridoxal-5-phosphate, and lipids in patients with coronary artery disease before and six month after coronary angioplasty followed by stent implantation. - Pteridines 2005; 16(4): 170-175.

A. Erglis, I. Zakke, A. Maca, A. Kalvelis, K. Trusinskis, S. Jegere, I. Narbute. Importance of the acute coronary syndrome register for the improvement of cardiac care in Latvia. - Seminars in Cardiology 2006; 12(1): 8–13.

A. Erglis, A. Dombrovskis, A. Rudzitis, P. Stradins. Percutaneous transcatheter closure of the iatrogenic aorto-coronary vein fistula with the Amplatzer vascular plug. - Seminars in Cardiology 2006; 12(1): 34-37
T.K. Steigen, M. Maeng, R. Wiseth, A.Erglis, I. Kumsars, I. Narbute, et al. Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation study. - Circulation 2006; 114(18): 1955-1961.
C. Spaulding, P. Henry, E. Teiger, K. Beatt, E. Bramucci, D. Carrie, M.S. Slama, B. Merkely, A. Erglis, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. - N Engl J Med 2006; 355(11): 1093-1104.

A. Erglis, I. Narbute, I. Kumsars, S. Jegere, I. Mintale, I. Zakke, U. Strazdins, A. Saltups. A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary artery stenosis. - J Am Coll Cardiol. 2007;50(6):491-497.
C. Stettler, S. Allemann, S. Wandel, A. Kastrati, M.C. Morice, A. Schömig, M.E. Pfisterer, G.W. Stone, M.B. Leon, J.S. de Lezo, J.-J. Goy, S.-J. Park, M. Sabaté, M.J. Suttorp, H. Kelbaek, C. Spaulding, M. Menichelli, P. Vermeersch, M.T. Dirksen, P. Cervinka, M. De Carlo, A. Erglis, T. Chechi, P. Ortolani, M.J. Schalij, P. Diem, B. Meier, S. Windecker, P. Jüni. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis BMJ 2008;337:a1331

Research Projects:

A. Erglis (Investigator of Project) Clinical efficacy and cost–effectiveness of coronary stenting with special stents in stable and unstable angina taking into account genetic and inflammatory risk factors. Latvian Council of Science (2001-2004).
A. Erglis (Head of Project) Clinical significance of atherosclerotic plaque modification before and during coronary artery complex lesion intervention and follow-up period and neointimal proliferation related to genetic and inflammatory risk factors. Latvian Council of Science (2004-2008).
A. Erglis (Member of Steering Committee) „Nordic Bifurcation Study: Randomized Study on Simple Versus Complex Stenting of Coronary Artery Bifurcation Lesions”, „Nordic Bifurcation Study II, III and IV” Nordic PCI Study Group (2005-present)

Last update 12.11.2008